Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial.

Abstract

BACKGROUND:

Elevated levels of osteoprotegerin, a secreted tumor necrosis factor-related molecule, might be associated with adverse outcomes in patients with coronary artery disease. We measured plasma osteoprotegerin concentrations on hospital admission, at discharge, and at 1 and 6 months after discharge in a predefined subset (n=5135) of patients with acute coronary syndromes in the PLATO (Platelet Inhibition and Patient Outcomes) trial.

METHODS AND RESULTS:

The associations between osteoprotegerin and the composite end point of cardiovascular death, nonprocedural spontaneous myocardial infarction or stroke, and non-coronary artery bypass grafting major bleeding during 1 year of follow-up were assessed by Cox proportional hazards models. Event rates of the composite end point per increasing quartile groups at baseline were 5.2%, 7.5%, 9.2%, and 11.9%. A 50% increase in osteoprotegerin level was associated with a hazard ratio (HR) of 1.31 (95% confidence interval [CI], 1.21-1.42) for the composite end point but was not significant in adjusted analysis (ie, clinical characteristics and levels of C-reactive protein, troponin T, NT-proBNP [N-terminal pro-B-type natriuretic peptide], and growth differentiation factor-15). The corresponding rates of non-coronary artery bypass grafting major bleeding were 2.4%, 2.2%, 3.8%, and 7.2%, with an unadjusted HR of 1.52 (95% CI, 1.36-1.69), and a fully adjusted HR of 1.26 (95% CI, 1.09-1.46). The multivariable association between the osteoprotegerin concentrations and the primary end point after 1 month resulted in an HR of 1.09 (95% CI, 0.89-1.33); for major bleeding after 1 month, the HR was 1.33 (95% CI, 0.91-1.96).

CONCLUSIONS:

In patients with acute coronary syndrome treated with dual antiplatelet therapy, osteoprotegerin was an independent marker of major bleeding but not of ischemic cardiovascular events. Thus, high osteoprotegerin levels may be useful in increasing awareness of increased bleeding risk in patients with acute coronary syndrome receiving antithrombotic therapy.

CLINICAL TRIAL REGISTRATION:

URL: http://www.clinicaltrials.gov. Unique identifier: NCT00391872.

• Authors: Thor Ueland, Axel Åkerblom, Tatevik Ghukasyan, Annika E Michelsen, Pål Aukrust, Richard C Becker, Maria Bertilsson, Anders Himmelmann, Stefan K James, Agneta Siegbahn, Robert F Storey, Frederic Kontny, Lars Wallentin, PLATO (Platelet Inhibition and Patient Outcomes) Trial Investigators
• Journal: Journal of the American Heart Association (J Am Heart Assoc) Vol. 7 Issue 2 (01 12 2018) ISSN: 2047-9980 [Electronic] England
• PMID: 29330256 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: © 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

Chemical References

• Biomarkers
• Osteoprotegerin
• Platelet Aggregation Inhibitors
• TNFRSF11B protein, human
• Clopidogrel
• Ticagrelor
• Aspirin

Topics

• Acute Coronary Syndrome (blood, diagnosis, drug therapy, mortality)
• Aged
• Aspirin (administration & dosage, adverse effects)
• Biomarkers (blood)
• Clopidogrel (administration & dosage, adverse effects)
• Drug Therapy, Combination
• Female
• Hemorrhage (chemically induced)
• Humans
• Male
• Middle Aged
• Osteoprotegerin (blood)
• Platelet Aggregation Inhibitors (administration & dosage, adverse effects)
• Risk Assessment
• Risk Factors
• Ticagrelor (administration & dosage, adverse effects)
• Time Factors
• Treatment Outcome
• Up-Regulation